Trials / Active Not Recruiting
Active Not RecruitingNCT05605782
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
ORION (Ozanimod Real-World Safety - A Post- Authorisation Multi-National Long-term Non-Interventional Study)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 9,000 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two population of participants: * Participants not exposed to ozanimod with RRMS who have received treatment with other S1P-receptor modulators disease modifying treatments (DMTs) * Participants not exposed to ozanimod with RRMS who have received treatment with other non-S1P-receptor modulators disease modifying treatments (DMTs)
Conditions
Timeline
- Start date
- 2021-09-02
- Primary completion
- 2033-07-26
- Completion
- 2033-07-26
- First posted
- 2022-11-04
- Last updated
- 2025-06-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05605782. Inclusion in this directory is not an endorsement.